Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Trial sponsor
AbbVie
Scientific Title
ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma: A Randomized Phase II Study of the EORTC Brain Tumor Group